Rational design and characterization of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Figueiredo, Ana C ^a   Clement, Cristina C ^b   Zakia, Sheuli ^b   Gingold, Julian ^c   Philipp, Manfred ^b   Pereira, Pedro J B ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DERIVATIVE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO ALANINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO CYSTEINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO GLUTAMINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO ISOLEUCINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO LEUCINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO PROLINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO SERINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO THREONINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGININE DEXTRO VALINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLALANINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLARGININE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLCYSTEINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLGLUTAMIC ACID; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLGLUTAMINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLGLYCINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLHISTIDINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLISOLEUCINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLLEUCINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLLYSINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLPHENYLALANINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLPROLINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLSERINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLTHREONINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLTRYPTOPHAN; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLTYROSINE; DEXTRO PHENYLALANYLPROLINE DEXTRO ARGINYLVALINE; PEPTIDE DERIVATIVE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTITHROMBIN; OLIGOPEPTIDE;

ARTICLE; COMPETITIVE INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HYDROGEN BOND; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; PROTEIN CLEAVAGE; CHEMISTRY; HUMAN;

ANTITHROMBINS; DRUG DESIGN; HUMANS; OLIGOPEPTIDES;

EID: 84858758675     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034354     Document Type: Article

References (42)

1. Mousa SA, (2010) Novel anticoagulant therapy: principle and practice. Methods Mol Biol 663: 157-179.
2. Steffel J, Braunwald E, (2011) Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J 32: 1968-1976.
3. Steffel J, Luscher TF, (2009) Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med (Hagerstown) 10: 616-623.
4. Srivastava S, Goswami LN, Dikshit DK, (2005) Progress in the design of low molecular weight thrombin inhibitors. Med Res Rev 25: 66-92.
5. Bode W, Mayr I, Baumann U, Huber R, Stone SR, et al. (1989) The refined 1.9 Å crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 8: 3467-3475.
6. Neises B, Tarnus C, Broersma RJ, Bald C, Remy JM, et al. (1993) The synthesis and anticoagulant activity of novel peptidylfluoroalkanes. Adv Exp Med Biol 340: 185-188.
7. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW 2nd, (1990) Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29: 7095-7101.
8. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, et al. (1991) Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J Mol Biol 221: 1379-1393.
9. Banner DW, Hadvary P, (1991) Crystallographic analysis at 3.0-Å resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 266: 20085-20093.
10. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, et al. (1981) Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101: 440-446.
11. Cuker A, (2011) Heparin-induced thrombocytopenia: present and future. J Thromb Thrombolysis 31: 353-366.
12. Babuin L, Pengo V, (2010) Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag 6: 813-819.
13. Stangier J, (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47: 285-295.
14. Ezekowitz M, Nagarakanti R, (2011) Dabigatran in atrial fibrillation: pharmacology and clinical trials. J Interv Card Electrophysiol 32: 173-180.
15. Hauel NH, Nar H, Priepke H, Ries U, Stassen J-M, et al. (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45: 1757-1766.
16. Bajusz S, Szell E, Barabas E, Bagdy D, (1982) Design and synthesis of peptide inhibitors of blood coagulations. Folia Haematol Int Mag Klin Morphol Blutforsch 109: 16-21.
17. Nieman MT, Burke F, Warnock M, Zhou Y, Sweigart J, et al. (2008) Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. J Thromb Haemost 6: 837-845.
18. Nieman MT, Warnock M, Hasan AAK, Mahdi F, Lucchesi BR, et al. (2004) The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther 311: 492-501.
19. Burke FM, Warnock M, Schmaier AH, Mosberg HI, (2006) Synthesis of novel peptide inhibitors of thrombin-induced platelet activation. Chem Biol Drug Des 68: 235-238.
20. Girnys EA, Sobczyk-Kojiro K, Mosberg HI, (2010) Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19. Chem Biol Drug Des 75: 35-39.
21. Isaacs RCA, Newton CL, Cutrona KJ, Mercer SP, Payne LS, et al. (2011) Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors. Bioorg Med Chem Lett 21: 1536-1540.
22. Andricopulo AD, Salum LB, Abraham DJ, (2009) Structure-based drug design strategies in medicinal chemistry. Curr Top Med Chem 9: 771-790.
23. Talele TT, Khedkar SA, Rigby AC, (2010) Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr Top Med Chem 10: 127-141.
24. Guichard G, Benkirane N, Zeder-Lutz G, van Regenmortel MH, Briand JP, et al. (1994) Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proc Natl Acad Sci U S A 91: 9765-9769.
25. Qiu X, Padmanabhan KP, Carperos VE, Tulinsky A, Kline T, et al. (1992) Structure of the hirulog 3-thrombin complex and nature of the S′ subsites of substrates and inhibitors. Biochemistry 31: 11689-11697.
26. Figueiredo AC, Clement CC, Philipp M, Pereira PJB, (2011) Crystallization and preliminary crystallographic characterization of three peptidic inhibitors in complex with α-thrombin. Acta Crystallogr Sect F Struct Biol Cryst Commun 67: 54-58.
27. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
28. Schärer K, Morgenthaler M, Seiler P, Diederich F, Banner D, et al. (2004) Enantiomerically pure thrombin inhibitors for exploring the molecular-recognition features of the oxyanion hole. Helv Chim Acta 87: 2517-2538.
29. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
30. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
31. Painter J, Merritt EA, (2006) Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 62: 439-450.
32. Painter J, Merritt EA, (2006) TLSMD web server for the generation of multi-group TLS models. J Appl Cryst 39: 109-111.
33. Sinauridze EI, Romanov AN, Gribkova IV, Kondakova OA, Surov SS, et al. (2011) New synthetic thrombin inhibitors: molecular design and experimental verification. PLoS ONE 6: e19969.
34. Bode W, Turk D, Karshikov A, (1992) The refined 1.9-Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1: 426-471.
35. Wagner J, Kallen J, Ehrhardt C, Evenou J-P, Wagner D, (1998) Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors. J Med Chem 41: 3664-3674.
36. Friedrich R, Steinmetzer T, Huber R, Stürzebecher J, Bode W, (2002) The methyl group of N[alpha](Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage. J Mol Biol 316: 869-874.
37. De Simone G, Balliano G, Milla P, Gallina C, Giordano C, et al. (1997) Human alpha-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D-Phe-Pro-alpha-azaLys p-nitrophenyl ester and N-carbobenzoxy-Pro-alpha-azaLys p-nitrophenyl ester: A kinetic, thermodynamic and X-ray crystallographic study. J Mol Biol 269: 558-569.
38. Chen ZG, Li Y, Mulichak AM, Lewis SD, Shafer JA, (1995) Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 Å resolution. Arch Biochem Biophys 322: 198-203.
39. Krishnan R, Tulinsky A, Vlasuk GP, Pearson D, Vallar P, et al. (1996) Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic. Protein Sci 5: 422-433.
40. Matthews JH, Krishnan R, Costanzo MJ, Maryanoff BE, Tulinsky A, (1996) Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1′ binding site. Biophys J 71: 2830-2839.
41. St Charles R, Matthews JH, Zhang E, Tulinsky A, (1999) Bound structures of novel P3-P1′ beta-strand mimetic inhibitors of thrombin. J Med Chem 42: 1376-1383.
42. Slon-Usakiewicz JJ, Sivaraman J, Li Y, Cygler M, Konishi Y, (2000) Design of P1′ and P3′ residues of trivalent thrombin inhibitors and their crystal structures. Biochemistry 39: 2384-2391.